Is there current research for the 20 percent of CML (Chronic Myelogenous Leukemia) patients who are resistant to imatinib mesylate (Gleevec)? CML expert Dr. Kathryn Kolibaba answers with an emphatic Yes!. Patient advocate Carol Preston speaks with Dr. Kolibaba as they discuss various studies directed at improving quality of life and managing Gleevec-resistant patients. The data is very, very promising, reports Dr. Kolibaba.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo